Log in

NYSE:BHVN - Biohaven Pharmaceutical Stock Price, Forecast & News

$54.50
-1.47 (-2.63 %)
(As of 01/24/2020 04:00 PM ET)
Today's Range
$53.39
Now: $54.50
$56.67
50-Day Range
$51.12
MA: $54.28
$57.29
52-Week Range
$34.06
Now: $54.50
$67.86
Volume731,764 shs
Average Volume710,185 shs
Market Capitalization$2.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.43
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:BHVN
CUSIPN/A
Phone203-404-0410

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.74 per share

Profitability

Net Income$-240,920,000.00

Miscellaneous

Employees63
Market Cap$2.85 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.


Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) announced its quarterly earnings data on Friday, November, 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by $0.47. View Biohaven Pharmaceutical's Earnings History.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Biohaven Pharmaceutical.

What price target have analysts set for BHVN?

12 equities research analysts have issued 1 year price objectives for Biohaven Pharmaceutical's shares. Their forecasts range from $50.00 to $100.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $73.55 in the next year. This suggests a possible upside of 34.9% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.

What is the consensus analysts' recommendation for Biohaven Pharmaceutical?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.

Has Biohaven Pharmaceutical been receiving favorable news coverage?

Press coverage about BHVN stock has trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biohaven Pharmaceutical earned a news impact score of -5.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Biohaven Pharmaceutical.

Are investors shorting Biohaven Pharmaceutical?

Biohaven Pharmaceutical saw a decrease in short interest in December. As of December 31st, there was short interest totalling 6,230,000 shares, a decrease of 6.9% from the December 15th total of 6,690,000 shares. Based on an average daily volume of 613,600 shares, the days-to-cover ratio is currently 10.2 days. Approximately 14.5% of the shares of the company are sold short. View Biohaven Pharmaceutical's Current Options Chain.

Who are some of Biohaven Pharmaceutical's key competitors?

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Netflix (NFLX), Global Blood Therapeutics (GBT), Roku (ROKU), Sarepta Therapeutics (SRPT) and ACADIA Pharmaceuticals (ACAD).

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the folowing people:
  • Dr. Vladimir Coric, CEO & Director (Age 48)
  • Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 55)
  • Dr. Charles Conway, Chief Scientific Officer (Age 57)
  • Mr. Clifford Bechtold, Chief Operating Officer
  • Mr. Matthew DeLawder, Director of Accounting

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.24%), Columbus Circle Investors (0.05%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Canton Hathaway LLC (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.

Which major investors are buying Biohaven Pharmaceutical stock?

BHVN stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Columbus Circle Investors, Canton Hathaway LLC, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $54.50.

How big of a company is Biohaven Pharmaceutical?

Biohaven Pharmaceutical has a market capitalization of $2.85 billion. The company earns $-240,920,000.00 in net income (profit) each year or ($6.15) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.View Additional Information About Biohaven Pharmaceutical.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.


MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  325 (Vote Underperform)
Total Votes:  608
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel